Brief: Aligos Therapeutics Announces Research Collaboration And Development Agreement With Xiamen Amoytop Biotech Co. Ltd. For Use Of Aligos’ Oligonucleotide Platform For The Treatment Of Liver Diseases
12/05/2023 22:10
May 12 (Reuters) - Aligos Therapeutics Inc ALGS.O :
* ALIGOS THERAPEUTICS ANNOUNCES RESEARCH COLLABORATION AND
DEVELOPMENT AGREEMENT WITH XIAMEN AMOYTOP BIOTECH CO. LTD. FOR
USE OF ALIGOS’ OLIGONUCLEOTIDE PLATFORM FOR THE TREATMENT OF
LIVER DISEASES
* ALIGOS THERAPEUTICS - AMOYTOP WILL RECEIVE OPTION TO
OBTAIN
EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE RESULTANT PRODUCTS
IN GREATER CHINA TERRITORY
* ALIGOS THERAPEUTICS INC - CO WILL ALSO RECEIVE AN UPFRONT
PAYMENT AND RESEARCH COLLABORATION FUNDING
* ALIGOS THERAPEUTICS - IN AGREEMENT, ALIGOS & AMOYTOP WILL
COLLABORATE ON RESEARCH & DEVELOPMENT OF OLIGONUCLEOTIDE
COMPOUNDS FOR TREATMENT OF LIVER DISEASES
* ALIGOS THERAPEUTICS INC- WILL BE ELIGIBLE TO RECEIVE UP TO
TOTAL
OF $109 MILLION IN DEVELOPMENT AND SALES MILESTONE PAYMENTS FOR
LICENSED PRODUCTS
* ALIGOS THERAPEUTICS INC - ALIGOS WILL RETAIN
REST-OF-WORLD
RIGHTS TO DEVELOP AND COMMERCIALIZE RESULTANT PRODUCTS
Source text for Eikon: ID:nGNX1flMNK
Further company coverage: ALGS.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on Aligos Therapeutics
See all newsUS FDA approves GSK's hepatitis B drug, offering patients chance to stop long-term treatment (updated)
U.S. RESEARCH ROUNDUP-Ciena Corp, Docusign, Snowflake
Brief: Aligos Therapeutics Announces First Participant Dosed In The Phase 1 Study Of Its Potentially Best-In-Class Antisense Oligonucleotide Alg-170675 By Its Partner Amoytop In China
Aligos Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Aligos Therapeutics Q2 net loss narrows on licensing revenue